GT200900008A - Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a - Google Patents

Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a

Info

Publication number
GT200900008A
GT200900008A GT200900008A GT200900008A GT200900008A GT 200900008 A GT200900008 A GT 200900008A GT 200900008 A GT200900008 A GT 200900008A GT 200900008 A GT200900008 A GT 200900008A GT 200900008 A GT200900008 A GT 200900008A
Authority
GT
Guatemala
Prior art keywords
aminopiridine
novedous
aurora
derivatives
inhibitory action
Prior art date
Application number
GT200900008A
Other languages
English (en)
Inventor
Iwasawa Yoshikazu
Kato Tetsuya
Kawanishi Nobuhiko
Masutani Kouta
Mita Takashi
Nonoshita Katsumasa
Ohkubo Mitsuru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900008A publication Critical patent/GT200900008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS NOVEDOSOS DE AMINOPIRIDINA QUE SON ÚTILES EN EL CAMPO FARMACÉUTICO YA QUE INHIBEN EL CRECIMIENTO DE CÉLULAS TUMORALES EN BASE A UNA ACCIÓN INHIBIDORA SELECTIVA DE LA AURORA A Y MUESTRAN EFECTO ANTITUMORAL.
GT200900008A 2006-08-31 2009-01-13 Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a GT200900008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006236472 2006-08-31
US92608607P 2007-04-25 2007-04-25

Publications (1)

Publication Number Publication Date
GT200900008A true GT200900008A (es) 2010-10-04

Family

ID=39136042

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900008A GT200900008A (es) 2006-08-31 2009-01-13 Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a

Country Status (27)

Country Link
US (2) US7915263B2 (es)
EP (2) EP2062887B1 (es)
JP (3) JP2008081492A (es)
KR (1) KR20090055562A (es)
CN (1) CN101528731B (es)
AR (1) AR062585A1 (es)
AU (1) AU2007289609B2 (es)
CA (1) CA2657469C (es)
CL (1) CL2007002519A1 (es)
CO (1) CO6190529A2 (es)
CR (1) CR10553A (es)
EC (1) ECSP099062A (es)
ES (1) ES2389515T3 (es)
GT (1) GT200900008A (es)
HN (1) HN2009000113A (es)
IL (1) IL196497A0 (es)
MA (1) MA30719B1 (es)
MX (1) MX2009000390A (es)
NO (1) NO20091301L (es)
NZ (1) NZ574081A (es)
PE (1) PE20080835A1 (es)
RU (1) RU2437880C2 (es)
SV (1) SV2009003152A (es)
TW (1) TW200817363A (es)
UA (1) UA95972C2 (es)
WO (2) WO2008026768A1 (es)
ZA (1) ZA200900126B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2714215A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
JP2011516464A (ja) * 2008-03-31 2011-05-26 サン・ファーマシューティカル・インダストリーズ・リミテッド モルフィナン類似体の改良された調製方法
ES2415907T3 (es) * 2008-07-24 2013-07-29 Nerviano Medical Sciences S.R.L. Combinación terapéutica que comprende un inhibidor de cinasas aurora y agentes antiproliferativos
KR101906146B1 (ko) 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
US9145414B2 (en) 2011-09-30 2015-09-29 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
TWI485146B (zh) 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
SG11201609336PA (en) 2014-05-13 2016-12-29 Sloan Kettering Inst Cancer Hsp70 modulators and methods for making and using the same
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光ａ激酶抑制劑
WO2016149922A1 (en) * 2015-03-25 2016-09-29 Intel Corporation Cluster computing service assurance apparatus and method
CN108250191B (zh) * 2018-03-15 2020-10-20 兰州大学 一种3,5-二取代的2-氨基-吡嗪化合物及其制备工艺与应用
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
JP2848958B2 (ja) 1990-09-28 1999-01-20 スミスクライン・ビーチャム・コーポレイション 水溶性カンプトテシン類似体、方法および手段
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
ATE309241T1 (de) 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
AU2002213467A8 (en) 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
KR100947185B1 (ko) * 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
AU2005264213A1 (en) * 2004-05-21 2006-01-26 Msd K.K. Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton
WO2006046735A1 (en) * 2004-10-29 2006-05-04 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
US7919487B2 (en) 2004-11-10 2011-04-05 Synta Pharmaceuticals Corporation Heteroaryl compounds
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US20060160869A1 (en) 2005-01-05 2006-07-20 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
AU2006241825A1 (en) * 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006129842A1 (ja) * 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives

Also Published As

Publication number Publication date
ZA200900126B (en) 2010-01-27
JP2010047602A (ja) 2010-03-04
ECSP099062A (es) 2009-02-27
CR10553A (es) 2009-06-28
RU2009111599A (ru) 2010-10-10
JPWO2008026769A1 (ja) 2010-01-21
JP2008081492A (ja) 2008-04-10
CN101528731A (zh) 2009-09-09
CA2657469C (en) 2013-07-02
US20080058347A1 (en) 2008-03-06
HN2009000113A (es) 2014-01-06
CA2657469A1 (en) 2008-03-06
MX2009000390A (es) 2009-01-29
NZ574081A (en) 2011-08-26
UA95972C2 (ru) 2011-09-26
EP2062887B1 (en) 2012-07-04
WO2008026769A1 (fr) 2008-03-06
CN101528731B (zh) 2014-05-07
CO6190529A2 (es) 2010-08-19
PE20080835A1 (es) 2008-06-14
US7915263B2 (en) 2011-03-29
WO2008026768A1 (en) 2008-03-06
AU2007289609B2 (en) 2012-02-02
EP2062887A1 (en) 2009-05-27
JP5256168B2 (ja) 2013-08-07
NO20091301L (no) 2009-04-30
RU2437880C2 (ru) 2011-12-27
TW200817363A (en) 2008-04-16
AU2007289609A1 (en) 2008-03-06
KR20090055562A (ko) 2009-06-02
IL196497A0 (en) 2009-09-22
SV2009003152A (es) 2009-04-28
CL2007002519A1 (es) 2008-02-08
EP2061782A1 (en) 2009-05-27
EP2061782A4 (en) 2010-03-31
ES2389515T3 (es) 2012-10-26
EP2062887A4 (en) 2010-03-31
AR062585A1 (es) 2008-11-19
MA30719B1 (fr) 2009-09-01
US20100016335A1 (en) 2010-01-21
JP4466782B2 (ja) 2010-05-26

Similar Documents

Publication Publication Date Title
GT200900008A (es) Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
SV2009003335A (es) Formulaciones para el cancer
GT200900146A (es) Inhibidores de la actividad de la akt
AR081678A1 (es) Metodos y composiciones para administracion intratecal de arisulfatasa a
CY1118062T1 (el) Συνθεσεις για την αντιμετωπιση της ναυτιας και του εμετου κεντρικης προελευσης
DK3120862T3 (da) Antimikrobielt peptid og sammensætninger deraf
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
ATE424159T1 (de) Katheter
CR11299A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
UA99284C2 (ru) ИНГИБИТОРЫ р70 S6-КИНАЗЫ
HK1160779A1 (en) Cdk inhibitor for the treatment of mesothelioma
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
TN2009000451A1 (en) Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
EA021554B9 (ru) Органические соединения и их применение для лечения hcv инфекции
RS53467B (en) USE OF AMISULPRID FOR TREATMENT OF Nausea and Vomiting Caused by Chemotherapy
ATE477805T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
DE602008005137D1 (de) Chinolonverbindung und pharmazeutische zusammensetzung
MX344189B (es) Formulaciones de mazindol.